Alert Fatigue Is a Clinical Risk, Not Just an Efficiency Issue
A 78% override rate across a retail network managing $20B+ in pharmacy spend means that high-severity drug interaction alerts — the ones that could prevent serious adverse events — are competing with dozens of low-signal warnings on every pharmacist's screen. When everything looks urgent, nothing is. State pharmacy boards and CMS both scrutinize DUR alert performance, and documentation of why high-severity alerts were bypassed is increasingly part of compliance reviews. Stale alert configurations that generate excessive noise are a liability, not just an annoyance.
Monthly Recalibration Driven by Override Data
An AI Labor Company agent extracts DUR alert calibration logic from Surescripts override histories and Magellan Rx alert configuration records — building a current-state picture of which alerts are generating the most overrides, at what severity levels, and with what documentation patterns. Each month, the agent identifies the highest-override, lowest-severity alerts: the ones that are generating noise without preventing harm. It generates recalibration recommendations with supporting override-rate data by alert type and queues the proposed configuration changes in Jira for your review and approval. TriZetto Facets integration ensures that approved changes are staged for production deployment. Nothing goes live without sign-off from your team.
What Clinical Clarity Is Worth Operationally
Reducing overall override rates from 78% to below 45% is a risk and compliance win, but it's also an operational one: pharmacists spend less time dismissing noise and more time acting on genuinely actionable alerts. Teams in this position typically see 65–85% reduction in manual alert review and configuration work once recurring recalibration is automated. The most direct value is in high-severity alert visibility — when the noise floor drops, the signals that matter become impossible to miss. The agent is live and running monthly recalibration cycles in approximately 6 weeks, with the first configuration recommendations typically ready before the end of the first cycle.
Who approves configuration changes before they go to production?
You do. Every recalibration recommendation is queued for your review in Jira with the supporting override-rate data that generated it. The agent stages proposed changes; your clinical team makes the final call before anything touches the live alert configuration.
How does this interact with NCPDP and state pharmacy board audit requirements?
The agent generates documentation for each recalibration cycle: which alerts were reviewed, what data supported the recommendation, and what action was taken. This creates a defensible audit trail showing that alert configurations are actively managed and data-driven — not set-and-forgotten.
Can the agent work with Surescripts data given HIPAA and data-use restrictions?
Yes. The agent works within your existing data access agreements with Surescripts. It processes override history data for configuration optimization purposes — the same data your team already uses for clinical program management — and doesn't create new data-sharing arrangements.